Neuberger Berman Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Neuberger Berman Group’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-16,000	Closed	-$397K	–	1607
2019 Q1	$397K	Buy	+16,000	New	+$401K	﹤0.01%	1304
2018 Q3	–	Sell	-23,406	Closed	-$1.06M	–	1727
2018 Q2	$1.06M	Buy	+23,406	New	+$1.14M	﹤0.01%	1214
2017 Q4	–	Sell	-11,000	Closed	-$906K	–	1836
2017 Q3	$906K	Buy	+11,000	New	+$872K	﹤0.01%	1177
2015 Q4	–	Sell	-160,959	Closed	-$14.8M	–	1586
2015 Q3	$14.8M	Buy	160,959 +152,170	+1,731%	+$13.2M	0.02%	707
2015 Q2	$772K	Buy	+8,789	New	+$752K	﹤0.01%	1247
2013 Q4	–	Sell	-4,800	Closed	-$292K	–	1676
2013 Q3	$292K	Buy	4,800 +1,687	+54%	+$120K	﹤0.01%	1410
2013 Q2	$209K	Buy	+3,113	New	+$140K	﹤0.01%	1485

Other funds holding CLVS

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Neuberger Berman Group's CLVS Position: Q2 2019 in Review

Neuberger Berman Group sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 16,000 shares — an estimated $397K sold.

Neuberger Berman Group first reported a position in CLVS in Q2 2013 and held it in 7 quarters. The position peaked at $14.8M in Q3 2015. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

Neuberger Berman Group reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
Neuberger Berman Group sold 16,000 Clovis Oncology, Inc. shares in Q2 2019, an estimated $397K.
Neuberger Berman Group first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 7 quarters.
Neuberger Berman Group's Clovis Oncology, Inc. position peaked at $14.8M in Q3 2015.
167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Neuberger Berman Group's 13F filing for Q2 2019, filed 13 Aug 2019.